Last reviewed · How we verify

Curcumin Lozenges

Tata Memorial Centre · Phase 3 active Small molecule

Curcumin, the active compound from turmeric, exerts anti-inflammatory and antioxidant effects by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine production.

Curcumin, the active compound from turmeric, exerts anti-inflammatory and antioxidant effects by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine production. Used for Oral mucositis prevention and treatment in cancer patients undergoing chemotherapy or radiotherapy, Oral inflammation and antimicrobial applications.

At a glance

Generic nameCurcumin Lozenges
Also known asLongvida (Pharmanza Herbal Pvt Ltd.)
SponsorTata Memorial Centre
Drug classNatural product/polyphenol anti-inflammatory agent
TargetNF-κB, multiple antioxidant pathways
ModalitySmall molecule
Therapeutic areaOncology, Oral health, Anti-inflammatory
PhasePhase 3

Mechanism of action

Curcumin is a polyphenolic compound that modulates multiple signaling pathways involved in inflammation and oxidative stress. It acts as a potent antioxidant and inhibits nuclear factor-kappa B (NF-κB) activation, thereby suppressing the expression of inflammatory mediators. The lozenge formulation allows for local delivery and systemic absorption to exert therapeutic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: